REMS
Absorption: 98% absorbed following oral administration.
Distribution: Highly bound to melanin-containing tissues (eyes, pigmented skin).
Half-Life: Children taking enzymeinducing anticonvulsants: 710 hr; Children taking enzyme inducers and valproic acid: 1527 hr; Children taking valproic acid: 4494 hr; Adults: 25.4 hr (during chronic therapy of lamotrigine alone).
Contraindicated in:
Use Cautiously in:
CV: arrhythmias, bradycardia, CARDIAC ARREST, heart block, QRS interval prolongation
Derm: photosensitivity, rash (higher incidence in children, patients taking valproic acid, high initial doses, or rapid dose increases), DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), STEVENS-JOHNSON SYNDROME (SJS), TOXIC EPIDERMAL NECROLYSIS (TEN)
EENT: blurred vision, double vision, rhinitis
GI: nausea, vomiting, HEPATIC FAILURE
GU: vaginitis
Hemat: HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
MS: arthralgia
Neuro: ataxia, dizziness, headache, ASEPTIC MENINGITIS, behavior changes, depression, drowsiness, insomnia, SUICIDAL THOUGHTS, tremor
Drug-drug:
Epilepsy
Bipolar Disorder
Lab Test Considerations:
NDC Code